CVE-2026-21923VulnerabilityPublished 20 Jan 2026

CVE-2026-21923: Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized update, insert or delete access to some of Oracle Life Sciences Central Designer accessible data as well as unauthorized read access to a subset of Oracle Life Sciences Central Designer accessible data.

Affects Oracle Life Sciences Central DesignerSource CVE Database V5

Not known to be exploited · CVSS 6.5 Medium.

Data as of 26 Oct 2026, 07:57 UTC

CVSS 3.1 base score

6.5Medium

How severe the flaw is on the 0–10 CVSS scale.

EPSS: 0.2% chance of exploitation in 30 days – higher than 18% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N

Attack Vector: Network
Attack Complexity: Low
Privileges Required: None
User Interaction: None
Scope: Unchanged
Confidentiality: Low
Integrity: Low
Availability: None

Bold values are the worst case: easiest to exploit or largest impact.

Attack Vector: Network: The vulnerable component is bound to the network stack and the set of possible attackers extends beyond the other options listed, up to and including the entire Internet. Such a vulnerability is often termed 'remotely exploitable' and can be thought of as an attack being exploitable at the protocol level one or more network hops away (e.g., across one or more routers).
Attack Complexity: Low: Specialized access conditions or extenuating circumstances do not exist. An attacker can expect repeatable success against the vulnerable component.
Privileges Required: None: The attacker is unauthorized prior to attack, and therefore does not require any access to settings or files to carry out an attack.
User Interaction: None: The vulnerable system can be exploited without any interaction from any user.
Scope: Unchanged: An exploited vulnerability can only affect resources managed by the same security authority. In this case, the vulnerable component and the impacted component are either the same, or both are managed by the same security authority.
Confidentiality: Low: There is some loss of confidentiality. Access to some restricted information is obtained, but the attacker does not have control over what information is obtained, or the amount or kind of loss is limited. The information disclosure does not cause a direct, serious loss to the impacted component.
Integrity: Low: Modification of data is possible, but the attacker does not have control over the consequence of a modification, or the amount of modification is limited. The data modification does not have a direct, serious impact on the impacted component.
Availability: None: There is no impact to availability within the impacted component.

Definitions: FIRST CVSS v3.1 specification.

Exploitation evidence

Disclosed: evidence found.
CVE published 20 Jan 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponised: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 2026-10-26.

Disclosed: The CVE record is public on cve.org. Its publication is t = 0.
Detectable: A public nuclei template can find exposed instances, for defenders and attackers alike.
Weaponised: Public exploit code exists in Metasploit or Exploit-DB, or CISA SSVC reports a public proof of concept.
Exploited in the wild: CISA KEV lists it, CISA SSVC rates exploitation active, or a source reports attacks.
Observed by OffSeq Mirage: OffSeq Mirage honeypot sensors recorded attack traffic for this CVE, or found exposed hosts without attack traffic.

Moments are spaced evenly, not to scale; a dashed line marks a gap of six months or more. Deltas count from t = 0. Sources that give only a date (CISA KEV, Exploit-DB, or a time of exactly 00:00Z) read “same day” rather than hours. Metasploit modules carry the flaw’s disclosure date, not their release date, and nuclei templates carry no date, so both appear above but not on the timeline.

What to do

Affected software

Product	Affected	Fixed in
Oracle CorporationOracle Life Sciences Central Designer	Affected =7.0.1.0	Fixed in–
Mavencom.oracle/life-sciences-central-designer`pkg:maven/com.oracle/life-sciences-central-designer`Other threats	Affected =7.0.1.0	Fixed in–

Check your own hosts for these packages with threat-finder (opens in a new tab), our free open-source scanner.

AI-suggested

1. Immediately restrict network access to Oracle Life Sciences Central Designer instances by implementing network segmentation and firewall rules to limit HTTP access only to trusted internal systems. 2. Monitor network traffic and application logs for unusual or unauthorized data modification activities, focusing on HTTP requests that attempt insert, update, or delete operations. 3. Apply Oracle vendor patches or updates as soon as they become available to address this vulnerability directly. 4. Implement Web Application Firewalls (WAF) with custom rules to detect and block suspicious HTTP requests targeting the affected product. 5. Conduct regular security assessments and penetration tests on the Oracle Life Sciences environment to identify and remediate similar access control weaknesses. 6. Enforce strict access control policies and consider additional authentication mechanisms if supported by the product. 7. Maintain an incident response plan tailored to data integrity and confidentiality breaches in clinical research environments. 8. Engage with Oracle support and subscribe to security advisories for timely updates on this vulnerability and related threats.

Description

CVE-2026-21923 is a medium-severity vulnerability affecting Oracle Life Sciences Central Designer version 7.0.1.0. It allows an unauthenticated attacker with network access via HTTP to perform unauthorized read, insert, update, or delete operations on some accessible data within the application. The vulnerability does not require user interaction or authentication, making it easily exploitable remotely. The CVSS 3.1 base score is 6.5, reflecting impacts on confidentiality and integrity but no impact on availability. There are no known exploits in the wild yet, and no patches have been linked at the time of publication.

Impact

For European organizations, especially those in pharmaceutical, biotechnology, and clinical research sectors, this vulnerability could lead to unauthorized disclosure and manipulation of sensitive clinical trial data or research information. Such data breaches could result in regulatory penalties under GDPR due to exposure of personal or sensitive health data. Integrity compromises could invalidate clinical trial results or research findings, delaying product development and damaging organizational reputation. The lack of availability impact reduces the risk of service disruption but does not diminish the severity of data compromise. Attackers exploiting this vulnerability could potentially alter trial parameters or results, causing significant downstream effects on patient safety and regulatory submissions. The ease of exploitation without authentication increases the risk of widespread attacks if network access is not properly restricted. Organizations relying on Oracle Life Sciences Central Designer must consider the potential for intellectual property theft, compliance violations, and operational disruptions.

References

oracle.com/security-alerts/cpujan2026.html (opens in a new tab)

Community reviews

Loading reviews…

Exploitation evidence

What to do

Affected software

Description

AI analysisMachine-generated, updated 28 Jan 2026, 20:17 UTC

Technical details

References

Community reviews

Related threats